Marinus Pharmaceuticals Inc (MRNS) ニュース

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher...

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure...

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

New U.S. patent issued for ZTALMY® (ganaxolone) oral titration regimens cover the treatment of a range of epilepsy disorders, expiring September...

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis...

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure...

Form 8-K - Current report

Form 8-K - Current report

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

Enrollment complete and on track to report topline data from the TrustTSC trial in tuberous sclerosis complex (TSC) in the first half of Q4 with...